Skip to main content

Table 4 Comparison of wild (CC) and heterozygous mutant (CG) genotypes of TNFAIP3 (rs5029939 C>G) SNP in chronic PIT patients as regards platelet counts and treatment response

From: Tumor necrosis factor induced protein 3 gene polymorphism and the susceptibility to chronic primary immune thrombocytopenia in Egyptian children: a case-control study

Chronic PIT patients

TNFAIP3 (rs5029939 C>G) SNP

Wild genotype (CC) [n = 31]

Mutant heterozygous genotype (CG) [n = 9]

p value

Sex [N (%)]

Males

15 (48.4)

2 (22.5)

0.256

Females

16 (51.6)

7 (77.8)

Age (mean ± SD)

7.77 ± 3.7

9.4 ± 4.74

0.235

Age at initial presentation (mean ± SD)

4.1 ± 2.63

5.91 ± 3.59

0.157

Duration of illness (mean ± SD)

3.7 ± 2.53

3.53 ± 2.61

0.702

Type of bleeding [N (%)]

Cutaneous

17 (54.8)

4 (44.4)

0.552

Mucous

1 (3.2)

1 (11.1)

Both

13 (41.9)

4 (44.4)

Severity of bleeding

(IWG bleeding score) [N (%)]

Severe life threatening (4b)

1 (3.2)

1 (11.1)

0.850

Severe non-life threatening(4a)

4 (12.9)

1 (11.1)

Moderate (3)

12 (38.7)

4 (44.4)

Mild (2)

13 (41.9)

3 (33.3)

Minor (1)

1 (3.2)

0 (0)

Splenectomy [N (%)]

1 (3.2)

1 (11.1)

0.404

HTN [N (%)]

9 (29)

4 (44.4)

0.437

Initial platelet count [× 109/L (mean ± SD)]

29.42 ± 19

43.89 ± 20.36

0.064

Platelets at the time of sampling [× 109/l (mean ± SD)]

111.7 ± 60.59

166.11 ± 97.66

0.177

Hemoglobin at the time of sampling [g/dl (mean ± SD)]

10.96 ± 1.42

11.07 ± 1.65

0.824

TLC at the time of sampling [× 109/l (mean ± SD)]

10.2 ± 4.42

9.33 ± 4.14

0.849

Laboratory response [N (%)]

Complete response

21 (67.74)

7 (77.7)

1

Response

5 (16.12)

1 (11.1)

0.697

No response

5 (16.12)

1 (11.1)

0.697

Treatment received

Initial treatment [N (%)]

Watchful waiting

5 (16.1)

6 (66.7)

0.007*

Corticosteroids

31 (100)

9 (100)

___

IVIg

4 (12.9)

0 (0)

---

Platelet transfusion

1 (3.2)

1 (11.1)

0.404

Maintenance treatment [N (%)]

Oral corticosteroids

26 (83.9)

9 (100)

0.570

Azathioprine (Imuran)

19 (61.3)

5 (55.6)

1

Cyclosporine (Sand immune)

5 (16.1)

3 (33.3)

0.348

Mycophenolate Mofetil (Cellcept)

0 (0)

1 (11.1)

---

Eltrombopag (Revolade)

2 (6.5)

0 (0)

---

Oral corticosteroids

26 (83.9)

9 (100)

0.570

  1. HTN hypertension, IVIg intravenous immunoglobulin
  2. * Statistically significant